These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

979 related articles for article (PubMed ID: 12942175)

  • 1. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.
    Stefani M; Dobson CM
    J Mol Med (Berl); 2003 Nov; 81(11):678-99. PubMed ID: 12942175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein aggregation and its consequences for human disease.
    Dobson CM
    Protein Pept Lett; 2006; 13(3):219-27. PubMed ID: 16515449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What the use of disease-unrelated model proteins can tell us about the molecular basis of amyloid aggregation and toxicity.
    Stefani M
    Ital J Biochem; 2003 Dec; 52(4):162-76. PubMed ID: 15141483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein misfolding, functional amyloid, and human disease.
    Chiti F; Dobson CM
    Annu Rev Biochem; 2006; 75():333-66. PubMed ID: 16756495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies.
    González-Montalbán N; Villaverde A; Aris A
    Biochem Biophys Res Commun; 2007 Apr; 355(3):637-42. PubMed ID: 17307135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and intermolecular dynamics of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange.
    Carulla N; Zhou M; Giralt E; Robinson CV; Dobson CM
    Acc Chem Res; 2010 Aug; 43(8):1072-9. PubMed ID: 20557067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
    Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
    Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world.
    Stefani M
    Biochim Biophys Acta; 2004 Dec; 1739(1):5-25. PubMed ID: 15607113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Process, Outcomes and Possible Elimination of Aggregation with Special Reference to Heme Proteins; Likely Remediations of Proteinopathies.
    Furkan M; Khan RH
    Curr Protein Pept Sci; 2020; 21(6):573-583. PubMed ID: 32013844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein aggregation as a cause for disease.
    Scheibel T; Buchner J
    Handb Exp Pharmacol; 2006; (172):199-219. PubMed ID: 16610361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the mysteries of protein folding and misfolding.
    Ecroyd H; Carver JA
    IUBMB Life; 2008 Dec; 60(12):769-74. PubMed ID: 18767168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining molecular dynamics simulations and experimental analyses in protein misfolding.
    Wille H; Dorosh L; Amidian S; Schmitt-Ulms G; Stepanova M
    Adv Protein Chem Struct Biol; 2019; 118():33-110. PubMed ID: 31928730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid peptides and proteins in review.
    Harrison RS; Sharpe PC; Singh Y; Fairlie DP
    Rev Physiol Biochem Pharmacol; 2007; 159():1-77. PubMed ID: 17846922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases.
    Ries HM; Nussbaum-Krammer C
    Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
    Matsuzaki K
    Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal amyloidosis: current views on pathogenesis and impact on diagnosis.
    Herrera GA; Teng J; Turbat-Herrera EA
    Contrib Nephrol; 2011; 169():232-246. PubMed ID: 21252523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies.
    Dumoulin M; Dobson CM
    Biochimie; 2004; 86(9-10):589-600. PubMed ID: 15556268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein aggregation.
    Merlini G; Bellotti V; Andreola A; Palladini G; Obici L; Casarini S; Perfetti V
    Clin Chem Lab Med; 2001 Nov; 39(11):1065-75. PubMed ID: 11831622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.